Floatz logo

Tucatinib

Breast Cancer

MedSIRSmall moleculePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

890 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Loratadine
Noha Mansour
Phase 2BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB

View all 50 →

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
invasive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →